This document describes the type of information required for the manufacture and control of active substances (existing or new chemical entities) used in a medicinal product.
Keywords: Active substance, chemistry, dossier, manufacture, quality control, impurities, specification
Current effective version (currently under consultation)
Guideline on the chemistry of active substances - First version
Guideline concerning the application of Directive 2001/83/EC with a view to the granting of a marketing authorisation for a medicinal product. This guideline replaces the ‘Note for guidance on chemistry of new active substances’ (CPMP/QWP/130/96, Rev 1) and ‘Chemistry of active substances’ (3AQ5a). It has been revised to cover new and existing active substances in one guideline.
English (EN) (203.56 KB - PDF)
Under consultation
Draft guideline on the chemistry of active substances - Revision 1
Guideline concerning the application of Directive 2001/83/EC with a view to the granting of a marketing authorisation for a medicinal product. This guideline replaces the ‘Note for guidance on chemistry of new active substances’ (CPMP/QWP/130/96, Rev 1) and ‘Chemistry of active substances’ (3AQ5a). It has been revised to cover new and existing active substances in one guideline.
Comments should be provided using this EUSurvey form. For any technical issues, please contact the EUSurvey Support.
English (EN) (363.64 KB - PDF)
Document history
Draft guideline on the chemistry of active substances - Revision 1
Guideline concerning the application of Directive 2001/83/EC with a view to the granting of a marketing authorisation for a medicinal product. This guideline replaces the ‘Note for guidance on chemistry of new active substances’ (CPMP/QWP/130/96, Rev 1) and ‘Chemistry of active substances’ (3AQ5a). It has been revised to cover new and existing active substances in one guideline.
Comments should be provided using this EUSurvey form. For any technical issues, please contact the EUSurvey Support.
English (EN) (363.64 KB - PDF)
Concept paper on the revision of the guideline on the chemistry of active substances - Revision 1
English (EN) (117.02 KB - PDF)
Guideline on the chemistry of active substances - First version
Guideline concerning the application of Directive 2001/83/EC with a view to the granting of a marketing authorisation for a medicinal product. This guideline replaces the ‘Note for guidance on chemistry of new active substances’ (CPMP/QWP/130/96, Rev 1) and ‘Chemistry of active substances’ (3AQ5a). It has been revised to cover new and existing active substances in one guideline.
English (EN) (203.56 KB - PDF)
Overview of comments received on 'Draft guideline on the chemistry of active substances’ (EMA/CHMP/QWP/96664/2015) - First version
Overview of comments received on 'Draft guideline on the chemistry of active substances’ (EMA/CHMP/QWP/96664/2015)
English (EN) (751.12 KB - PDF)
Draft guideline on the chemistry of active substances (human) - First version
This guideline replaces the ‘Note for guidance on chemistry of new active substances’ (CPMP/QWP/130/96, Rev 1) and ‘Chemistry of active substances’ (3AQ5a). It has been revised to cover new and existing active substances in one guideline.
English (EN) (188.39 KB - PDF)
Concept paper on the need for a single note for guidance on the chemistry of active substances - First version
English (EN) (81.29 KB - PDF)
Chemistry of active substances - Superseded document
English (EN) (36.37 KB - PDF)
Chemistry of new active substances - Superseded document
English (EN) (207.78 KB - PDF)
Related content
- Quality: active substance
- Guideline on control of impurities of pharmacopoeial substances: compliance with the european pharmacopoeia general monograph "substances for pharmaceutical use" and general chapter "control of impurities in substance...
- Eudralex - Volume 4 Good manufacturing practice (GMP) Guidelines, Annex 16: Certification by a Qualified Person and Batch Release
- Active substance master file procedure
- ICH M7 Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk
- ICH Q1A (R2) Stability testing of new drug substances and drug products
- ICH Q1B Photostability testing of new active substances and medicinal products
- ICH Q2(R1) Validation of analytical procedures: text and methodology
- ICH Q3A (R2) Impurities in new drug substances
- ICH Q3C (R5) Residual solvents
- ICH Q6A Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances
- ICH Q7 Good manufacturing practice for active pharmaceutical ingredients
- ICH Q11 Development and manufacture of drug substances (chemical entities and biotechnological/biological entities)
- Investigation of chiral active substances
- ICH M7 Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk - Scientific guideline
- Plastic primary packaging materials
- Quality of water for pharmaceutical use
- Setting specifications for related impurities in antibiotics
- Specification limits for residues of metal catalysts
- Stability testing of existing active ingredients and related finished products
- Summary of requirements for active substances in the quality part of the dossier
- Template for the qualified person's (QP) declaration concerning good manufacturing practice compliance of active substance manufacture 'The QP declaration template'